Abstract
Acute lymphoblastic leukemia (ALL) is a clonal proliferation of early B- and T-lymphocyte progenitors and results in the accumulation of leukemic blasts in the bone marrow and various extramedullary sites. It affects both children and adults, with peak prevalence between the ages of 2 to 5 years. Despite current treatment protocols achieving rapid cytoreduction in the vast majority of patients, serious acute and late complications are frequent and resistance to chemotherapy often develops. In contrast to the successes obtained with pediatric patients, treatment outcomes for adults remain poor with only 40% of patients being long-term survivors. Extensive research in the field of ALL has helped understand the mechanisms that control leukemic cells, facilitating the design of new drugs that specifically interfere with leukemic pathways and overcome chemo-resistance induced by common treatment regimens. Herein, we review the current status of the development of novel anti-leukemic agents, with emphasis on small molecular inhibitors that have already translated into clinical trials and are in the advanced stages of preclinical development. Challenges to successful development of each strategy are discussed.
Keywords: Acute lymphoblastic leukemia, treatment, novel therapy, small molecular inhibitors
Current Cancer Drug Targets
Title: Emerging Treatments in Acute Lymphoblastic Leukemia
Volume: 9 Issue: 1
Author(s): R. Crazzolara and L. Bendall
Affiliation:
Keywords: Acute lymphoblastic leukemia, treatment, novel therapy, small molecular inhibitors
Abstract: Acute lymphoblastic leukemia (ALL) is a clonal proliferation of early B- and T-lymphocyte progenitors and results in the accumulation of leukemic blasts in the bone marrow and various extramedullary sites. It affects both children and adults, with peak prevalence between the ages of 2 to 5 years. Despite current treatment protocols achieving rapid cytoreduction in the vast majority of patients, serious acute and late complications are frequent and resistance to chemotherapy often develops. In contrast to the successes obtained with pediatric patients, treatment outcomes for adults remain poor with only 40% of patients being long-term survivors. Extensive research in the field of ALL has helped understand the mechanisms that control leukemic cells, facilitating the design of new drugs that specifically interfere with leukemic pathways and overcome chemo-resistance induced by common treatment regimens. Herein, we review the current status of the development of novel anti-leukemic agents, with emphasis on small molecular inhibitors that have already translated into clinical trials and are in the advanced stages of preclinical development. Challenges to successful development of each strategy are discussed.
Export Options
About this article
Cite this article as:
Crazzolara R. and Bendall L., Emerging Treatments in Acute Lymphoblastic Leukemia, Current Cancer Drug Targets 2009; 9 (1) . https://dx.doi.org/10.2174/156800909787314057
DOI https://dx.doi.org/10.2174/156800909787314057 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Bioactive Polysaccharides From Natural Resources For Cancer Therapy
Bioactive polysaccharides from natural resources exhibit diverse therapeutic properties including anticancer, antioxidant, antidiabetic, immunostimulatory activity, and promotion of wound healing. In the past decades, most studies focused on the extraction and identification of polysaccharides, as well as their biological activities. A large number of bioactive polysaccharides with different structural features ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Innovative Drug Research Propelling a New Era of Precision Oncology
Drug-oncology research is leading a new era of precision medicine, becoming a frontier hotspot in cancer treatment. Advancements in molecular biology, genomics, and medicinal chemistry have driven revolutionary changes in cancer cognition and treatment strategies. Gene-targeted drugs provide more precise treatments, improving survival rates for certain cancers. Network pharmacology offers ...read more
Novel Targets in Cancer Immunotherapy
Cancer immunotherapy, particularly immune checkpoint inhibitors (ICIs), has greatly revolutionized therapeutic strategies in the field of cancer. Current targets of FDA-approved ICIs include CTLA-4, PD-1/PDl-1, and LAG-3. However, the prognosis of cancer patients, especially with solid tumors, remains unfavorable due to the intrinsic and acquired resistance. For the past decades, ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Plant-food-derived Bioactives in Managing Hypertension: From Current
Findings to Upcoming Effective Pharmacotherapies
Current Topics in Medicinal Chemistry Functional Chemical Groups that May Likely Become a Source for the Synthesis of Novel Central Nervous System (CNS) Acting Drugs
Central Nervous System Agents in Medicinal Chemistry Recent Advances in Pulmonary Hypertension Therapy
Recent Patents on Cardiovascular Drug Discovery Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance
Current Pharmaceutical Design Editorial: Perioperative Pharmacological Management: From Prescription Medications to Dietary Supplements
Current Clinical Pharmacology Artery of Percheron Infarction: A Characteristic Pattern of Ischemia and Variable Clinical Presentation: A Literature Review
Current Medical Imaging Patent Selections
Recent Patents on Food, Nutrition & Agriculture Atrial Natriuretic Peptide: Structure, Function, and Physiological Effects: A Narrative Review
Current Cardiology Reviews Mechanisms and Medical Management of Exercise Intolerance in Hypertrophic Cardiomyopathy
Current Pharmaceutical Design Structure-Function Relationships of Iodinated Contrast Media and Risk of Nephrotoxicity
Current Medicinal Chemistry Effects of Flavonoids in Experimental Models of Arterial Hypertension
Current Topics in Medicinal Chemistry Effects of Physical Exercise on Depressive Symptoms and Biomarkers in Depression
CNS & Neurological Disorders - Drug Targets Targets and Tools: Recent Advances in the Development of Anti-HCV Nucleic Acids
Infectious Disorders - Drug Targets AMPA Glutamate Receptors and Neuropathic Pain
Mini-Reviews in Medicinal Chemistry Mas Receptor Agonists as Novel Antihypertensive Agents
Current Hypertension Reviews The Urokinase Receptor System, A Key Regulator at the Intersection between Inflammation, Immunity, and Coagulation
Current Pharmaceutical Design Similarities and Differences Between Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation
Current Vascular Pharmacology Industrial Chemicals and Acute Lung injury with a Focus on Exposure Scenarios
Current Respiratory Medicine Reviews Reducing Perioperative Myocardial Infarction with Anesthetic Drugs and Techniques
Current Drug Targets Urotensin II: A Vascular Mediator in Health and Disease
Current Vascular Pharmacology